{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:26:22Z","timestamp":1772025982079,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alcohol can diminish individual health from the fetus to old age and affects a wide range of structures and processes in the central nervous system. The role of dopamine D2 and D3 receptors in addictive diseases is the subject of many years of research. Among many psychotropic medications, cariprazine actually preferentially binds to D3 receptors, and its binding is stronger than that of any other antipsychotic, and even that of dopamine itself. Some data indicate that cariprazine and its effects associated with D3 partial agonism, could improve the domain of cognitive and depressive symptoms, as well as in the sphere of motivation, reward and cravings reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Cases presentations<\/jats:title>\n                    <jats:p>This case report describes four individual cases of patients who were alcohol addicts, with multiple hospitalizations during their treatment of dependence. All four patients were treated during the years with many different pharmacologic protocols, involving antipsychotics (olanzapine, quetiapine), mood stabilizers (carbamazepine, lamotrigine), anxiolytics (clonazepam, bromazepam), SSRI antidepressants (fluoxetine, paroxetine, escitalopram), but without achieving of the alcohol abstinence. Only by adding of cariprazine in the protocol, with almost total exclusion of other phychopharmacs, they achieved stable alcohol abstinence. Similarly, across all four cases, a marked improvement in depressive and cognitive symptoms was observed, and although each patient had been treated with antidepressants for many years, meaningful improvement occurred only after the introduction of cariprazine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The consistent achievement of full abstinence across all four patients suggests that it may have potential relevance in the management of alcohol use disorder (AUD). However, in the future, well conducted and highly controlled studies are needed to explore a potential cariprazine\u2019s role and its place in the management of alcohol dependence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1772314","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:36:38Z","timestamp":1772022998000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Four cases for cariprazine and alcohol use disorder"],"prefix":"10.3389","volume":"17","author":[{"given":"Sreten","family":"Vicentic","sequence":"first","affiliation":[{"name":"Clinic of Psychiatry, University Clinical Center of Serbia","place":["Belgrade, Serbia"]},{"name":"Faculty of Medicine, University of Belgrade","place":["Belgrade, Serbia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S2215-0366(18)30337-7","article-title":"Use The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis forthe Global Burden of Disease Study 2016","volume":"5","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/add.14234","article-title":"Global statistics on alcohol, tobacco and illicit drug use: 2017 status report","volume":"113","author":"Peacock","year":"2018","journal-title":"Addiction"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.06.032","article-title":"Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: A 12-week, randomized, placebo-controlled trial","volume":"133","author":"Likhitsathian","year":"2013","journal-title":"Drug Alcohol Depend"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.157.1.127","article-title":"Striatal dopaminergic D(2) receptor density measured by [(123)I]iodobenzamide SPECT in the prediction of treatment outcome of alcoholdependent patients","volume":"157","author":"Guardia","year":"2000","journal-title":"Am J Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-012-0797-0","article-title":"Direct and indirect interactions of the dopamine D(3) receptor with glutamate pathways: implications for the treatment of schizophrenia","volume":"386","author":"Sokoloff","year":"2013","journal-title":"N.-S. Arch Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.brainresrev.2004.12.033","article-title":"The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence","volume":"49","author":"Heidbreder","year":"2005","journal-title":"Brain Res Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1096\/fj.06-6110com","article-title":"The dopamine D3 receptor plays an essential role in alcohol-seeking and relapse","volume":"20","author":"Vengeliene","year":"2006","journal-title":"FASEB J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1017\/s1092852916000043","article-title":"Mechanism of action of cariprazine","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr"},{"key":"B10","article-title":"Cariprazine may decrease substance abuse in patients with bipolar I disorder","volume":"36","author":"Sanders","year":"2019","journal-title":"Psychiatr Times"},{"key":"B11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pnpbp.2013.08.012","article-title":"What is the role of the D3 receptor in addiction? A mini review of PET studies with [11C]-(+)-PHNO","volume":"52","author":"Payer","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/1381612828666220623092853","article-title":"Atypical antipsychotic drugs in dual disorders: current evidence for clinical practice","volume":"28","author":"Martinotti","year":"2022","journal-title":"Curr Pharm Design"},{"key":"B13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.neubiorev.2020.04.024","article-title":"Dopamine D3 receptor-based medication development for the treatment of opioid use disorder: Rationale, progress, and challenges","volume":"114","author":"Galaj","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1177\/2045125320905752","article-title":"Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data","volume":"10","author":"Stahl","year":"2020","journal-title":"Ther Adv Psychopharmacol"},{"key":"B15","article-title":"Cariprazine (RGH-188), a D3-preferring dopamine D3\/D2 receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats","volume":"226","author":"Rom\u00e1n","year":"2012","journal-title":"Psychopharmacology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S298005","article-title":"Cariprazine in three acute patients with schizophrenia: A real-world experience","volume":"17","author":"Montes","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B17","article-title":"Cariprazine as a maintenance treatment in dual schizophrenia : A 6-month observational study in patients with schizophrenia and cannabis use","author":"Szerman","year":"2024","journal-title":"Int Clin Psychopharmacol"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.727666","article-title":"Case report: cariprazine in a patient with schizophrenia, substance abuse, and cognitive dysfunction","volume":"12","author":"Rodriguez Cruz","year":"2021","journal-title":"Front Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","first-page":"100048","DOI":"10.1016\/j.psycom.2022.100048","article-title":"Cariprazine in the treatment of psychosis with comorbid cannabis use: A case report","volume":"2","author":"Gentile","year":"2022","journal-title":"Psychiatry Res Commun"},{"key":"B20","article-title":"Clinical experiences with cariprazine in schizophrenic patients with comorbid substance abuse","volume":"5","author":"Carmassi","year":"2019","journal-title":"Evidence-Based Psychiatr Care"},{"key":"B21","first-page":"8","article-title":"Experiences of switching to cariprazine","volume":"5","author":"Di Sciascio","year":"2019","journal-title":"Evidence-Based Psychiatr Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14656566.2023.2266359","article-title":"The role of the D3 dopamine receptor and its partial agonist cariprazine in patients with schizophrenia and substance use disorder","volume":"24","author":"Grunze","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2021.803208","article-title":"Reducing addiction in bipolar disorder via hacking the dopaminergic system","volume":"12","author":"Grunze","year":"2021","journal-title":"Front Psychiatry"},{"key":"B24","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41386-020-00890-7","article-title":"A \u201cNo brainer\u201d? Using brain-based, relapse-relevant, endophenotypes in medication development: testing a dopamine d3- preferring partial agonist (cariprazine) against cue -triggered limbic activation in cocaine patients","volume":"45","author":"Childress","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"B25","unstructured":"VRAYLAR FDA label\n          \n          \n          \n          2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.3390\/ph18070995","article-title":"Transdiagnostic efficacy of cariprazine: a systematic review and meta-analysis of efficacy across ten symptom domains","volume":"18","author":"Barab\u00e1ssy","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/S0920-9964(12)70588-1","article-title":"Cariprazine, a D3\/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics","volume":"136","author":"Kiss","year":"2012","journal-title":"Schizophr Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181e7810a","article-title":"Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis","volume":"30","author":"Zhornitsky","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1300917","article-title":"The effect of olanzapine on craving and alcohol consumption","volume":"31","author":"Hutchison","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3180ca86e5","article-title":"A double blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism","volume":"27","author":"Kampman","year":"2007","journal-title":"J Clin Psychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1999.tb04349.x","article-title":"Psychometric properties of the penn alcohol craving scale","volume":"23","author":"Flannery","year":"1999","journal-title":"Alcohol Clin Exp Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2024.1382013","article-title":"A 12-month longitudinal naturalistic follow-up of cariprazine in schizophrenia","volume":"15","author":"Carmassi","year":"2024","journal-title":"Front Psychiatry"},{"key":"B33","first-page":"100094","article-title":"Cariprazine in offender patient with acute psychosis and aggressive behavior: Case report","volume":"2","author":"Machetanz","year":"2022","journal-title":"Psychiatry Res Case Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.878889","article-title":"Case report: functional and symptomatic improvement with cariprazine in various psychiatric patients: A case series","volume":"13","author":"Vannucchi","year":"2022","journal-title":"Front Psychiatry"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20451253221132087","article-title":"Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study","volume":"12","author":"Pappa","year":"2022","journal-title":"Ther Adv Psychopharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.10136","article-title":"Real-world evidence and real-world data for evaluating drug safety and effectiveness","volume":"320","author":"Corrigan-Curay","year":"2018","journal-title":"J Am Med Assoc"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216","article-title":"Real-world evidence\u2014what is it and what can it tell us","volume":"375","author":"Sherman","year":"2016","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s11017-007-9029-x","article-title":"Does evidence-based medicine apply to psychiatry","volume":"28","author":"Gupta","year":"2007","journal-title":"Theor Med Bioeth"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/20451253241232563","article-title":"Drug safety in older patients with alcohol use disorder: a retrospective cohort study","volume":"14","author":"Schr\u00f6der","year":"2024","journal-title":"Ther Adv Psychopharmacol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1186\/s12888-024-06188-y","article-title":"Influence of inpatient withdrawal treatment on drug safety in alcohol use disorder - a quasi-experimental pre-post study","volume":"24","author":"Schr\u00f6der","year":"2024","journal-title":"BMC Psychiatry"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/20420986241311214","article-title":"Drug interactions in patients with alcohol use disorder: results from a real-world study on an addiction-specific ward","volume":"16","author":"Schr\u00f6der","year":"2025","journal-title":"Ther Adv Drug Saf"},{"key":"B42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1772314\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T12:36:41Z","timestamp":1772023001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1772314\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":42,"alternative-id":["10.3389\/fpsyt.2026.1772314"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1772314","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"article-number":"1772314"}}